| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.79M | 18.72M | 31.25M | 29.75M | 6.76M | 6.48M |
| Gross Profit | 4.06M | 15.93M | 13.17M | 17.79M | 2.05M | 1.35M |
| EBITDA | -56.29M | -51.72M | -87.98M | -84.36M | -64.46M | -50.01M |
| Net Income | -134.65M | -132.06M | -88.48M | -86.91M | -90.86M | -51.15M |
Balance Sheet | ||||||
| Total Assets | 189.15M | 220.33M | 197.41M | 254.60M | 251.21M | 70.78M |
| Cash, Cash Equivalents and Short-Term Investments | 99.81M | 113.59M | 119.11M | 217.57M | 191.41M | 54.13M |
| Total Debt | 2.37M | 2.60M | 3.50M | 2.25M | 2.89M | 14.15M |
| Total Liabilities | 57.41M | 64.77M | 40.23M | 56.98M | 53.87M | 33.13M |
| Stockholders Equity | 131.74M | 155.55M | 157.18M | 197.62M | 197.34M | 37.65M |
Cash Flow | ||||||
| Free Cash Flow | -45.86M | -20.20M | -79.63M | -68.17M | -52.44M | -39.09M |
| Operating Cash Flow | -9.99M | -20.07M | -78.33M | -67.57M | -52.13M | -38.63M |
| Investing Cash Flow | -61.76M | -69.77M | 46.22M | 12.63M | -167.63M | 6.39M |
| Financing Cash Flow | 74.32M | 74.54M | 26.71M | 72.87M | 225.05M | 18.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $257.22M | ― | -87.94% | ― | 3.89% | 7.92% | |
55 Neutral | $244.83M | -1.65 | -101.41% | ― | -47.56% | -65.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $202.44M | -5.03 | ― | ― | 22.56% | 41.62% | |
46 Neutral | $127.89M | ― | -44.24% | ― | 0.93% | 13.99% | |
43 Neutral | $193.75M | -2.62 | -207.57% | ― | 54.17% | -2.43% | |
41 Neutral | $45.35M | -0.50 | -48.46% | ― | 0.85% | 29.83% |
On October 14, 2025, Aclaris Therapeutics will hold an R&D Day to showcase their innovative therapeutic developments. The company is advancing several promising product candidates, including bosakitug, ATI-052, and ATI-2138, which have the potential to be best-in-class treatments for various immune-mediated diseases. Aclaris is well-financed with a cash runway extending into 2028, and they are poised for significant growth with multiple clinical programs and strategic partnerships on the horizon.
The most recent analyst rating on (ACRS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immuno-inflammatory diseases, leveraging a robust research and development engine to address unmet patient needs.
On July 29, 2025, Aclaris Therapeutics announced the top-line results of their Phase 2a clinical trial for ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, in subjects with moderate to severe atopic dermatitis. The trial showed that ATI-2138 was well tolerated with no severe adverse events, and demonstrated significant efficacy, with a mean improvement in Eczema Area and Severity Score (EASI) of 77% over 12 weeks, excluding outliers. This development could enhance Aclaris’ positioning in the treatment of immuno-inflammatory diseases, offering a promising therapeutic option for patients and potentially impacting future market strategies.
The most recent analyst rating on (ACRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.